Aisling Capital Management LP Viracta Therapeutics, Inc. Transaction History
Aisling Capital Management LP
- $243 Million
- Q3 2024
A detailed history of Aisling Capital Management LP transactions in Viracta Therapeutics, Inc. stock. As of the latest transaction made, Aisling Capital Management LP holds 288,571 shares of VIRX stock, worth $63,485. This represents 0.03% of its overall portfolio holdings.
Number of Shares
288,571
Previous 288,571
-0.0%
Holding current value
$63,485
Previous $155,000
57.42%
% of portfolio
0.03%
Previous 0.07%
Shares
1 transactions
Others Institutions Holding VIRX
# of Institutions
41Shares Held
5.63MCall Options Held
0Put Options Held
0-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.52MShares$334,4520.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA954KShares$209,9860.0% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA690KShares$151,7350.09% of portfolio
-
Stonepine Capital Management, LLC Bend, OR500KShares$110,0000.07% of portfolio
-
Laurion Capital Management LP New York, NY332KShares$73,0810.0% of portfolio
About Viracta Therapeutics, Inc.
- Ticker VIRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,558,200
- Market Cap $8.26M
- Description
- Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...